Table 6.
Thromboembolic events in patients with Gastric cancer
| Clinical Variables | Number of Patients | Thromboembolic Events | p-Value | |
|---|---|---|---|---|
| (n) | (%) | |||
| Chemotherapy Regimen | ||||
| ECF | 26 | 8 | 30.8 | 0.5982 |
| Cisplatin-Docetaxel-5FU | 137 | 28 | 20.4 | |
| Cisplatin-5FU | 20 | 4 | 20 | |
| Others | 8 | 0 | 0 | |
| Disease Stage | ||||
| Early Stage | 35 | 11 | 31.4 | 0.0916 |
| Metastatic | 156 | 29 | 18.5 | |
| Khorana Risk Score | ||||
| Lowa | 1 | 1 | 0.5331 | |
| Intermediate | 101 | 19 | 18.8 | |
| High | 89 | 20 | 22.5 | |
| Age (years) | ||||
| Missed | 1 | 0.8647 | ||
| < 50 | 90 | 18 | 18.5 | |
| ≥ 50 | 100 | 21 | 23.5 | |
ECF Epirubicin, Cisplatin and 5-Flurouracil, 5-FU 5-Flurouracil
a Only one patient and had thrombosis